A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Moderate to Severe Refractory Autoimmune Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China
Contact: Principal Investigator (Huji Xu)